You are here

Eli Lilly

Trajenta Meets Primary Endpoint in Cardiovascular Trial

Trajenta Meets Primary Endpoint in Cardiovascular Trial

CP Wire

Boehringer Ingelheim

Flag link:

Trajenta Meets Primary Endpoint in Cardiovascular Trial

Boehringer Ingelheim

Flag link:

Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger

Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger

Endpoints

Flag link:

Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later

Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later

Fierce Pharma

Flag link:

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

CP Wire

Boehringer Ingelheim

Flag link:

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

Boehringer Ingelheim

Flag link:

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Endpoints

ankylosing spondylitis

Flag link:

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

Fierce Pharma

Flag link:

ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis

ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis

Fierce Pharma

Boehringer Ingelheim

Flag link:

5 Biggest Blockbuster Diabetes Drugs of the Future

5 Biggest Blockbuster Diabetes Drugs of the Future

Motley Fool

Boehringer Ingelheim

Flag link:

Merck & Co. could try to acquire Elanco (13.5bn)

Merck & Co. could try to acquire Elanco (13.5bn)

GoinPharma

Flag link:

Novo reveals more Ozempic data on change in body weight by baseline BMI

Novo reveals more Ozempic data on change in body weight by baseline BMI

Yahoo/Reuters

Flag link:

U.S. District Court rules in favor of Lilly's Alimta patent

U.S. District Court rules in favor of Lilly's Alimta patent

Yahoo/Reuters

Flag link:

Lilly's lupus treatment succeeds in mid-stage trial

Lilly's lupus treatment succeeds in mid-stage trial

Reuters

clinical trials

Flag link:

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

CP Wire

Alzheimer's disease

BACE inhibitors

Flag link:

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Alzheimer's disease

Flag link:

Lilly's experimental colitis drug posts positive Phase 2 data

Lilly's experimental colitis drug posts positive Phase 2 data

Biopharma Dive

ulcerative colitis

monoclonal antibodies

Flag link:

Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning

Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning

Xconomy

rheumatoid arthritis

Flag link:

Novo Nordisk's oral diabetes drug beats Jardiance in study

Novo Nordisk's oral diabetes drug beats Jardiance in study

Yahoo/Reuters

Flag link:

Lilly's cancer business loses its chief just as it's leaning on oncology for growth

Lilly's cancer business loses its chief just as it's leaning on oncology for growth

Fierce Pharma

Flag link:

Pages